# Lyell Immunopharma

a late-stage clinical company advancing next-generation chimeric antigen receptor and TCR-T cell therapies, with a June 2026 safety update on LYL273 in relapsed solid tumours; its epigenetic reprogramming technology addresses T-cell exhaustion, the central obstacle in solid-tumour cell therapy.

Source: https://en.bioecon.ru/companies/lyell-immunopharma/
Updated: 2026-07-11

- Country: United States
- Ticker: LYEL

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $50 million equity private placement tranche closed in March 2026 | https://ir.lyell.com/news-releases/news-release-details/lyell-immunopharma-acquires-exclusive-global-rights-next, https://ir.lyell.com/node/9136/pdf, https://www.globenewswire.com/news-release/2026/08/06/3340726/0/en/Lyell-Immunopharma-Reports-Business-Highlights-and-Financial-Results-for-the-Second-Quarter-2026.html, https://www.sec.gov/Archives/edgar/data/1806952/000162828026017244/lyel-20260312x8kexx991.htm |
| Capacity | more than 1,200 CAR T-cell doses per year | https://ir.lyell.com/static-files/bddca8f8-1778-4048-8112-880812b9e93c, https://www.biospace.com/press-releases/lyell-immunopharma-provides-update-on-safety-profile-of-lyl273-in-relapsed-or-refractory-metastatic-colorectal-cancer-and-amends-phase-1-trial-to-phase-1-2-expansion, https://www.stocktitan.net/sec-filings/LYEL/10-k-lyell-immunopharma-inc-files-annual-report-04421e18ea60.html |
| Regulatory approval | Fast Track designation for LYL273 for mCRC | https://ir.lyell.com/news-releases/news-release-details/lyell-immunopharma-acquires-exclusive-global-rights-next, https://www.biospace.com/press-releases/lyell-immunopharma-provides-update-on-safety-profile-of-lyl273-in-relapsed-or-refractory-metastatic-colorectal-cancer-and-amends-phase-1-trial-to-phase-1-2-expansion, https://www.sec.gov/Archives/edgar/data/1806952/000162828026017244/lyel-20260312x8kexx991.htm, https://www.stocktitan.net/sec-filings/LYEL/10-k-lyell-immunopharma-inc-files-annual-report-04421e18ea60.html |
| Regulatory approval | RMAT and Fast Track designations for ronde-cel for R/R LBCL | https://ir.lyell.com/news-releases/news-release-details/lyell-immunopharma-reports-business-highlights-and-financial-10, https://www.biospace.com/press-releases/lyell-immunopharma-provides-update-on-safety-profile-of-lyl273-in-relapsed-or-refractory-metastatic-colorectal-cancer-and-amends-phase-1-trial-to-phase-1-2-expansion, https://www.sec.gov/Archives/edgar/data/1806952/000162828026017244/lyel-20260312x8kexx991.htm |
| Production site | LyFE Manufacturing Center (LyFE) in Bothell, Washington | https://ir.lyell.com/static-files/bddca8f8-1778-4048-8112-880812b9e93c, https://www.stocktitan.net/sec-filings/LYEL/10-k-lyell-immunopharma-inc-files-annual-report-04421e18ea60.html |
| Revenue | $36,000 for the full year 2025 | https://ir.lyell.com/news-releases/news-release-details/lyell-immunopharma-reports-q4-and-full-year-2025-business-and, https://www.globenewswire.com/news-release/2026/08/06/3340726/0/en/Lyell-Immunopharma-Reports-Business-Highlights-and-Financial-Results-for-the-Second-Quarter-2026.html, https://www.tickergate.com/stocks/lyel/revenue |

Independent sources: biospace.com, globenewswire.com, ir.lyell.com, sec.gov, stocktitan.net, tickergate.com

## Technologies

- [TCR therapy (T-cell receptor engineered T cells)](https://en.bioecon.ru/technology/tcr-therapy/)